β-胡萝卜素直接结合NLRP3吡啶结构域抑制痛风性关节炎
本研究通过基于结构的虚拟筛选约62,800种化合物,发现β-胡萝卜素可选择性直接结合NLRP3的吡啶结构域(KD=3.41×10-6),抑制多种激活剂(包括MSU晶体)诱导的NLRP3炎症小体活化。在痛风性关节炎小鼠模型中,口服β-胡萝卜素减轻MSU晶体诱导的炎症症状(P<0.05),并减少痛风患者滑液细胞的IL-1β分泌(P<0.05)。
要点
- β-胡萝卜素直接结合NLRP3吡啶结构域,KD=3.41×10-6。
- β-胡萝卜素抑制MSU晶体等诱导的NLRP3炎症小体活化(P<0.05)。
- 口服β-胡萝卜素减轻小鼠痛风性关节炎炎症并减少人滑液细胞IL-1β分泌。
核心结论
- β-胡萝卜素是NLRP3的选择性直接抑制剂,结合NLRP3吡啶结构域是治疗NLRP3炎症小体驱动疾病(包括痛风性关节炎)的新型药理策略。
研究设计与样本
- 基于结构的虚拟筛选分析约62,800种化合物以筛选高效NLRP3抑制剂。
- 采用免疫印迹和酶联免疫吸附试验检测caspase 1-p10和IL-1β产生以评估NLRP3炎症小体活化。
- 使用两种痛风性关节炎模型和MSU晶体注射诱导的气囊炎症模型进行体内实验。
- 使用痛风患者原代滑液细胞评估NLRP3炎症小体抑制在人类痛风中的相关性。
主要发现
- β-胡萝卜素抑制小鼠骨髓来源原代巨噬细胞中多种激活剂(包括MSU晶体)诱导的NLRP3炎症小体活化(P<0.05)。
- 表面等离子共振分析显示β-胡萝卜素直接结合NLRP3的吡啶结构域(KD=3.41×10-6)。
- 分子建模和突变实验揭示了β-胡萝卜素与NLRP3吡啶结构域的相互作用模式。
- 口服β-胡萝卜素减轻痛风性关节炎小鼠模型中MSU晶体诱导的炎症症状(P<0.05),与其对炎症组织中NLRP3炎症小体的抑制作用相关。
- β-胡萝卜素减少痛风患者滑液细胞IL-1β分泌(P<0.05),显示其在人类痛风中的抑制功效。
临床怎么用
- β-胡萝卜素作为NLRP3直接抑制剂,可能为痛风性关节炎提供新的治疗选择,但需进一步临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The NLRP3 inflammasome is closely linked to the pathophysiology of a wide range of inflammatory diseases. This study was undertaken to identify small molecules that directly bind to NLRP3 in order to develop pharmacologic interventions for NLRP3-related diseases. METHODS: A structure-based virtual screening analysis was performed with ~62,800 compounds to select efficient NLRP3 inhibitors. The production of caspase 1-p10 and interleukin-1β (IL-1β) was measured by immunoblotting and enzyme-linked immunosorbent assay to examine NLRP3 inflammasome activation. Two gouty arthritis models and an air pouch inflammation model induced by monosodium urate monohydrate (MSU) crystal injection were used for in vivo experiments. Primary synovial fluid cells from gout patients were used to determine the relevance of NLRP3 inflammasome inhibition in human gout. RESULTS: Beta-carotene (provitamin A) suppressed the NLRP3 inflammasome activation induced by various activators, including MSU crystals, in mouse bone marrow-derived primary macrophages (P < 0.05). Surface plasmon resonance analysis demonstrated the direct binding of β-carotene to the pyrin domain (PYD) of NLRP3 (KD = 3.41 × 10-6 ). Molecular modeling and mutation assays revealed the interaction mode between β-carotene and the NLRP3 PYD. Inflammatory symptoms induced by MSU crystals were attenuated by oral administration of β-carotene in gouty arthritis mouse models (P < 0.05), correlating with its suppressive effects on the NLRP3 inflammasome in inflamed tissues. Furthermore, β-carotene reduced IL-1β secretion from human synovial fluid cells isolated from gout patients (P < 0.05), showing its inhibitory efficacy in human gout. CONCLUSION: Our results present β-carotene as a selective and direct inhibitor of NLRP3, and the binding of β-carotene to NLRP3 PYD as a novel pharmacologic strategy to combat NLRP3 inflammasome-driven diseases, including gouty arthritis.
引用
- Yang G, Lee HE, Moon SJ, et al. Direct Binding to NLRP3 Pyrin Domain as a Novel Strategy to Prevent NLRP3-Driven Inflammation and Gouty Arthritis. Arthritis Rheumatol. 2020. PMID: 32134203. doi:10.1002/art.41245
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。